A recent target trial emulation among veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin therapy did not improve insulin discontinuation rates. Researchers compared the effects of adding GLP-1RAs against adding SGLT-2i or DPP-4i therapy, but saw no significant difference in outcomes.
Subscribe
Chronic Illness Management
Therapy Options
GLP-1 Initiation Did Not Improve Insulin Discontinuation Rates Among Veterans with Type 2 Diabetes
Photo by Newswise
Key Takeaways:
- GLP-1 receptor agonists did not increase insulin discontinuation rates.
- Veterans with type 2 diabetes were the focus of this study.
- A target trial emulation was used to compare treatment strategies.
- Results showed no advantage over SGLT-2i or DPP-4i in discontinuing insulin.
- Basal insulin therapy served as the primary treatment.
Background on Type 2 Diabetes Treatments
Type 2 diabetes management often involves a combination of medications, including injectable treatments like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and oral therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) or dipeptidyl peptidase-4 inhibitors (DPP-4i). Veterans with type 2 diabetes face unique challenges, and clinicians are continually searching for approaches that might reduce reliance on insulin.
Design of the Target Trial Emulation
In this study, researchers used a target trial emulation to compare how well three classes of medications—GLP-1RAs, SGLT-2i, and DPP-4i—could help veterans on basal insulin therapy achieve independence from insulin. This design aimed to mimic the conditions of a randomized controlled trial, offering real-world insights based on clinical data.
Study Findings
According to the study’s findings, adding GLP-1 receptor agonists did not improve the likelihood of discontinuing insulin compared with adding SGLT-2i or DPP-4i. While each medication class is recognized as an important tool in treating type 2 diabetes, none outperformed the others in helping veterans halt their insulin therapy.
Implications and Next Steps
For veterans and clinicians focused on easing the burden of insulin use, these results signal that simply adding a GLP-1RA to ongoing basal insulin may not be the tipping point for discontinuation. Instead, patients and physicians may consider other factors, such as individual health needs, side-effect profiles, and additional research, to guide future treatment decisions.
